Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report.
Loading...
Embargo End Date
ICR Authors
Authors
Begum, P
Cui, W
Popat, S
Cui, W
Popat, S
Document Type
Journal Article
Date
2022-09-01
Date Accepted
2022-06-28
Abstract
gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration.
Citation
JTO Clinical and Research Reports, 2022, 3 (9), pp. 100376 -
Source Title
JTO Clinical and Research Reports
Publisher
ELSEVIER
ISSN
2666-3643
eISSN
2666-3643
2666-3643
2666-3643